KR20230141301A - Composition for preventing, ameliorating or treating cardiovascular disease comprising egg shell membrane as effective component - Google Patents

Abstract

The present invention relates to a composition for preventing, improving and treating cardiovascular diseases containing egg shell membrane as an active ingredient. As a result of a human application test of the egg shell membrane, the content of apolipoprotein B and eosinophils in the blood decreased after 4 weeks of ingestion of the egg shell membrane. In addition, since it has the effect of significantly reducing systolic blood pressure, it can be usefully used as a health functional food or medicine for preventing, improving, or treating cardiovascular diseases.

Description

Composition for preventing, ameliorating or treating cardiovascular disease comprising egg shell membrane as effective component}

The present invention relates to a composition for preventing, improving and treating cardiovascular diseases containing egg shell membrane as an active ingredient.

Cardiovascular disease refers to diseases that occur in the heart and major arteries. Heart disease includes congenital heart disease that occurs at birth and acquired heart disease that develops throughout life. Just as the structure of the heart can be divided into the heart muscle, cardiovascular vessels, valves, and the conduction system responsible for the heart's electrical signals, heart disease is also a disease that occurs in each area. Can be classified. Major vascular diseases are diseases in which major arteries such as the aorta, pulmonary artery, carotid artery, cerebral artery, renal artery, and lower extremity artery are blocked, stretched, or ruptured, causing bleeding. Main causes include (athero) arteriosclerosis, high blood pressure, degenerative changes, and heredity. According to statistics on causes of death published by the National Statistical Office in 2009, circulatory system diseases, including hypertensive diseases, ischemic heart diseases, and cerebrovascular diseases, are the second leading cause of death in Korea, after malignant tumors. , the mortality rate of circulatory system diseases increases significantly in women over the age of 65. Risk factors related to cardiovascular disease, especially atherosclerosis, are age (middle-aged or older), gender (male), high blood pressure, hyperlipidemia, diabetes, smoking, lack of exercise, and obesity. Major cardiovascular diseases include high blood pressure, ischemic heart disease, coronary artery disease, angina pectoris, myocardial infarction, atherosclerosis, arteriosclerosis, cerebrovascular disease, stroke, and arrhythmia.

Arteriosclerosis is a disease in which the walls thicken and harden, losing elasticity. It is a type of aging phenomenon, and the main causes are high blood pressure, obesity, and diabetes. It is the main cause of blood flow disorders, blood clot formation, cerebral stroke, and myocardial infarction.

Atherosclerosis is a disease in which oil accumulates in blood vessels and the walls of blood vessels become hard. Cholesterol is deposited in the intima, the innermost membrane of blood vessels, and cell proliferation occurs, forming a porridge-like atheroma. The inner surface of these blood vessels becomes gritty and the walls thicken, narrowing the inner diameter through which blood flows, causing problems in blood circulation. When the fibrous membrane surrounding the atheroma (called a sclerotic plaque) ruptures, a blood clot (blood clot) forms within the blood vessel. Additionally, bleeding occurs inside the atheroma, causing the inner diameter of the blood vessel to rapidly narrow or become blocked. It mainly occurs in the blood vessels that supply blood to the heart, blood vessels that supply blood to the brain, blood vessels that supply blood to the kidneys, and peripheral blood vessels, causing ischemic heart disease, stroke, renal failure, and limb ischemic artery disease.

High blood pressure refers to the force that blood exerts on the walls of blood vessels, and is diagnosed as high blood pressure if the average value of multiple blood pressure measurements is 140 mmHg systolic or 90 mmHg or more diastolic.

Ischemic heart disease refers to a condition in which the myocardium does not function properly because the amount of oxygen required for the heart muscle is not supplied to the heart muscle due to various causes. The most common cause is narrowing or blockage of the coronary arteries that supply blood to the heart.

Coronary artery disease is a comprehensive term for diseases caused by abnormalities in the coronary arteries (heart arteries), which are blood vessels that supply oxygen and nutrients to the heart muscle. Representative examples include angina pectoris and myocardial infarction.

Angina is a disease in which the inner diameter of the coronary artery narrows due to arteriosclerosis, preventing the heart muscle from being supplied with the necessary amount of blood. Usually, when the heart needs a lot of nutrients and oxygen, such as when exercising, sufficient blood cannot be supplied to the heart muscle through narrowed blood vessels, causing heart dysfunction. Chest pain such as ‘chest tightness’ may occur and heart function may deteriorate.

Myocardial infarction is a disease in which the coronary artery (cardiac artery) that supplies blood to the heart is blocked and the myocardium dies. Oil residues accumulated on the walls of heart arteries narrowed by arteriosclerosis burst and meet blood to form blood clots. The blood clots completely block the flow of blood, causing necrosis (rot) of the heart muscle, causing chest pain. do.

Arrhythmia is an abnormal pulse that occurs due to repeated contraction and relaxation of the heart muscle. Usually, the rhythm is irregular or the speed is too fast or too slow. For regular contraction of the heart muscle, there is a cardiac conduction system within the heart that voluntarily generates regular electrical signals and transmits them throughout the heart. If there is an abnormality in this cardiac conduction system, an arrhythmia occurs.

Meanwhile, the eggshell membrane is the membrane on the inside of the eggshell of a bird's egg, and is made up of two inner and outer shells. The outer shell membrane adheres closely to the inner surface of the eggshell, and the inner shell membrane covers egg white. The egg shell membrane is made from a strong fibrous protein and has ovo keratin and ovo mucin as its main components. The egg shell membrane is known to have a function of promoting skin regeneration, as it has long been used to treat scratches and other injuries in wrestling rooms, and has recently been used to promote the production of type (III) collagen, also called fetal collagen. It has been reported to have a promoting effect.

Korean Patent No. 1104773 discloses a composition for preventing and treating high blood pressure containing cinnamalcohol, and Korean Patent No. 2341031 discloses a composition for preventing or treating cardiovascular disease containing Boesenbergia Rotunda extract or its active flavonoids. This is disclosed. However, there has been no disclosure regarding a composition for preventing, improving, or treating cardiovascular disease containing the eggshell membrane of the present invention as an active ingredient.

The present invention was developed in response to the above-mentioned needs, and the present invention provides a composition for preventing, improving, and treating cardiovascular diseases containing egg shell membrane as an active ingredient, and 4 weeks after ingestion of the egg shell membrane, apolipoprotein B in the blood The present invention was completed by confirming that not only the content of eosinophils was reduced, but also the systolic blood pressure was significantly reduced.

In order to achieve the above object, the present invention provides a health functional food composition for preventing or improving cardiovascular disease containing egg shell membrane as an active ingredient.

Additionally, the present invention provides a pharmaceutical composition for preventing or treating cardiovascular diseases containing eggshell membrane as an active ingredient.

The present invention relates to a composition for preventing, improving and treating cardiovascular diseases containing egg shell membrane as an active ingredient. As a result of a human application test of the egg shell membrane, the content of apolipoprotein B and eosinophils in the blood decreased after 4 weeks of ingestion of the egg shell membrane. In addition, it has the effect of significantly reducing systolic blood pressure.

The present invention relates to a health functional food composition for preventing or improving cardiovascular diseases containing egg shell membrane as an active ingredient.

The cardiovascular disease is preferably selected from arteriosclerosis, hypertension, dyslipidemia, atherosclerosis, ischemic heart disease, coronary artery disease, angina pectoris, myocardial infarction, heart failure, and arrhythmia, but is not limited thereto.

The egg shell membrane can be any avian egg shell membrane, and is preferably an egg shell membrane obtained from one or more selected from eggs, quail eggs, duck eggs, and ostrich eggs, but is not limited thereto. The egg shell membrane is not particularly distinguished, but is a membrane located on the inside of the egg shell, and is preferably used in powder form, but is not limited thereto.

The composition is preferably manufactured in a dosage form selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage, but is not limited thereto.

Examples of foods to which the eggshell membrane of the present invention can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, and tea. , it may be in any form selected from drinks, alcoholic beverages, and vitamin complexes, and includes all health functional foods in the conventional sense.

The health functional foods include various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alkynic acid and its salts, organic acids, and protective colloidal thickeners. , pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Additionally, it may contain pulp for the production of natural fruit juice and vegetable drinks. These ingredients can be used independently or in combination.

The health functional food of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients. The natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. Sweeteners include natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame.

Additionally, the present invention relates to a pharmaceutical composition for preventing or treating cardiovascular diseases containing egg shell membrane as an active ingredient.

In addition to the above active ingredients, it may further include a carrier, excipient, or diluent. The pharmaceutical composition of the present invention may be in various oral or parenteral dosage forms. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain one or more compounds and at least one excipient, such as starch, calcium carbonate, sucrose, or lactose ( It is prepared by mixing lactose, gelatin, etc. Additionally, in addition to simple excipients, lubricants such as magnesium stearate, talc, etc. are also used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. there is. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspension solvents may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, twin 61, cacao, laurel, glycerol, gelatin, etc. can be used.

The composition of the present invention can be administered orally or parenterally, and when administered parenterally, it is preferable to select the injection method for external application to the skin or intraperitoneal, rectal, intravenous, muscle, subcutaneous, intrauterine dura, or intracerebrovascular injection.

The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity, and activity of the patient's disease. , can be determined based on factors including sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, drugs used simultaneously, and other factors well known in the field of medicine. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.

The dosage of the composition of the present invention can vary depending on the patient's weight, age, gender, health condition, diet, administration time, administration method, excretion rate, and severity of the disease.

Hereinafter, the present invention will be described in more detail using examples. These examples are only for illustrating the present invention in more detail, and it is obvious to those skilled in the art that the scope of the present invention is not limited thereto.

Human application test subjects: People aged 20 to 75 years with high blood uric acid levels (asymptomatic hyperuricemia)

Test group: Eggshell membrane powder (EM) 100% (500mg per tablet)

Control group: Corn starch (EM placebo) 100% (500 mg per tablet)

Food intake method: 2 tablets (1,000 mg/day) once a day, taken for 4 weeks. Eggshell membrane powder or corn starch was administered to the test group (n=6) and control group (n=5), respectively, under the same conditions.

Example 1. Comparison of blood content of apolipoprotein B before and after ingestion of egg shell membrane

Comparison of apolipoprotein B content in blood Blood apolipoprotein B content (mean ± standard deviation) Test group (n=6) Control group (n=5) Before intake 110.8±37.3 124.7±29.0 After intake 102.8±35.0 120.8±26.6 Before intake - After intake 8.0±3.7 4.0±10.3 p value 0.0031 0.4377

In the test group, the average blood apolipoprotein B decreased after egg shell membrane consumption compared to before consumption, and the difference was statistically significant (p=0.0031). In contrast, in the control group administered a placebo, the blood content of apolipoprotein B decreased after ingestion of egg shell membrane, but there was no statistically significant difference (p=0.4377).

Example 2. Comparison of blood content of eosinophils before and after ingestion of egg shell membrane

Comparison of Eosinophil Content in Blood Eosinophil content in blood (mean ± standard deviation) Test group (n=6) Control group (n=5) Before intake 3.1±1.0 1.9±0.9 After intake 2.2±1.1 1.9±1.0 Before intake - After intake 0.9±0.8 0.0±0.1 p value 0.0428 0.8712

In the test group, the content of eosinophils in the blood decreased after ingestion of eggshell membrane compared to before ingestion, and the difference was statistically significant (p=0.0428). In contrast, in the control group administered placebo, there was no statistically significant difference in the content of eosinophils in the blood after ingestion of eggshell membrane (p=0.8712).

Example 3. Comparison of systolic blood pressure before and after ingestion of egg shell membrane

Systolic blood pressure comparison Comparison of systolic blood pressure (mean ± standard deviation) Test group (n=6) Control group (n=5) Before intake 125.3±12.3 128.2±5.0 After intake 117.0±8.3 132.0±6.7 Before intake - After intake 8.3±7.4 -3.8±4.7 p value 0.0043 0.1422

In the test group, systolic blood pressure decreased after egg shell membrane consumption compared to before consumption, and the difference was statistically significant (p=0.0043). In contrast, in the control group administered a placebo, there was little change in systolic blood pressure before and after egg shell membrane ingestion (p=0.1422).

Claims (6)

A health functional food composition for preventing or improving cardiovascular disease containing egg shell membrane as an active ingredient. The cardiovascular system of claim 1, wherein the cardiovascular disease is any one selected from arteriosclerosis, hypertension, dyslipidemia, atherosclerosis, ischemic heart disease, coronary artery disease, angina pectoris, myocardial infarction, heart failure, and arrhythmia. Health functional food composition for preventing or improving disease. The health functional food composition for preventing or improving cardiovascular disease according to claim 1, wherein the egg shell membrane is an avian egg shell membrane. The health functional food composition for preventing or improving cardiovascular disease according to claim 1, wherein the composition is manufactured in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage. A pharmaceutical composition for preventing or treating cardiovascular disease containing egg shell membrane as an active ingredient. The pharmaceutical composition for preventing or treating cardiovascular diseases according to claim 5, further comprising a carrier, excipient, or diluent in addition to the active ingredient.